$アルタミラ・セラピューティクス(CYTO.US)$Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal 3 MINUTES AGO, 8:47 AM EDT VIA GLOBENEWSWIRE
Revolutionary Collaboration: Altamira Therapeutics and Univercells Group Join Forces on Nanoparticle-Delivered mRNA Vaccines. In an era where medical innovation is more critical than ever, a groundbreaking collaboration between Altamira Therapeutics Ltd. and Univercells Group has emerged, signaling a potential leap forward in the way vaccines are delivered. Announced on March 25, 2024, this partnership aims to ha...
$アルタミラ・セラピューティクス(CYTO.US)$Altamira Therapeutics Ltd stock is currently priced at $2.46, with a 24-hour trading volume of 56.48M. It has seen a +41.16%increased in the last 24 hours and a+35.67% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $1.70 pivot point. If it approaches the $1.84 resistance level, significant changes may occur.
Dragana :
Altamira Therapeutics Ltd Stock (CYTO) Forecast The Altamira Therapeutics Ltd (CYTO) stock price forecast for the next 12 months is generally positive, with an average analyst price target of $21.33, representing a +829.46% increase from the current price of $2.295. The highest analyst price target is $26.56, and the lowest is $16.10. Based on our technical indicators, the current sentiment is bullish and CYTO could hit $26.56 in 2025. This might be a good time to open fresh positions on CYTO, as trading bullish markets is always a lot easier.
アルタミラ・セラピューティクスに関するコメント
News
3 MINUTES AGO, 8:47 AM EDT
VIA GLOBENEWSWIRE
Therapeutics Business Forms Groundbreaking Collaboration With Global Biotech Company
In an era where medical innovation is more critical than ever, a groundbreaking collaboration between Altamira Therapeutics Ltd. and Univercells Group has emerged, signaling a potential leap forward in the way vaccines are delivered. Announced on March 25, 2024, this partnership aims to ha...
まだコメントはありません